Shree Ganesh Remedies Ltd Valuation Shifts Signal Price Attractiveness Decline

Valuation Metrics Reflect Expensive Re-rating

As of 9 February 2026, Shree Ganesh Remedies Ltd trades at ₹470.50, up 3.74% from the previous close of ₹453.55. However, this price appreciation accompanies a significant re-rating in valuation metrics. The company’s P/E ratio has surged to 33.35, a level that categorises it as expensive relative to its historical valuation and many peers within the Pharmaceuticals & Biotechnology sector. Similarly, the price-to-book value ratio stands at 3.93, reinforcing the premium investors are currently paying for the stock.

Other valuation multiples such as EV to EBIT (25.93) and EV to EBITDA (18.12) also indicate a stretched valuation, especially when compared to more attractively priced competitors. For instance, Fermenta Biotec, a peer in the same sector, trades at a P/E of 8.62 and EV to EBITDA of 7.07, both significantly lower, signalling a more reasonable valuation.

Peer Comparison Highlights Relative Expensiveness

Within the Pharmaceuticals & Biotechnology sector, Shree Ganesh Remedies Ltd’s valuation stands out as expensive but not the most extreme. Shukra Pharmaceuticals and NGL Fine Chem are classified as very expensive, with P/E ratios of 63.74 and 38.20 respectively, and EV to EBITDA multiples exceeding 24. Kwality Pharma, by contrast, is rated fair with a P/E of 24.87 and EV to EBITDA of 13.95, while several other peers such as Venus Remedies and Lincoln Pharma are deemed attractive with P/E ratios below 13 and EV to EBITDA multiples under 7.

This peer context suggests that while Shree Ganesh Remedies Ltd is not the most overvalued stock in its sector, its current valuation premium is significant and warrants careful consideration by investors, especially given the company’s recent financial performance.

Financial Performance and Returns: A Mixed Picture

Shree Ganesh Remedies Ltd’s return profile over various time horizons presents a mixed narrative. The stock has delivered a robust 91.77% return over three years and an impressive 246.29% over five years, substantially outperforming the Sensex’s 38.13% and 64.75% returns respectively over the same periods. This long-term outperformance underscores the company’s growth potential and operational resilience.

However, more recent returns have been less encouraging. Over the past year, the stock has declined by 40.36%, sharply underperforming the Sensex’s 7.07% gain. Year-to-date, the stock has marginally risen by 1.58%, while the Sensex has fallen 1.92%. The one-month return of 5.05% is positive but modest, and the one-week return of 12.57% significantly outpaces the Sensex’s 1.59%, suggesting some short-term momentum.

This volatility and recent underperformance relative to the benchmark raise concerns about the sustainability of the current valuation premium.

Profitability and Efficiency Metrics

From a profitability standpoint, Shree Ganesh Remedies Ltd reports a return on capital employed (ROCE) of 16.87% and a return on equity (ROE) of 11.79%. These figures indicate moderate efficiency in generating returns from capital and equity, though they are not exceptional within the sector. The absence of a dividend yield further limits income appeal for investors seeking steady cash flows.

Moreover, the company’s PEG ratio stands at zero, which may reflect either a lack of earnings growth guidance or an anomaly in calculation, warranting further scrutiny by investors.

Valuation Grade Downgrade and Market Sentiment

MarketsMOJO has recently downgraded Shree Ganesh Remedies Ltd’s Mojo Grade from Sell to Strong Sell as of 12 January 2026, reflecting deteriorating sentiment and valuation concerns. The company’s market cap grade remains low at 4, consistent with its micro-cap status and relatively limited liquidity.

This downgrade aligns with the shift in valuation grade from fair to expensive, signalling caution for investors considering new positions at current price levels.

Price Range and Volatility Considerations

The stock’s 52-week price range of ₹381.10 to ₹950.00 highlights significant volatility, with the current price of ₹470.50 closer to the lower end of this spectrum. This wide trading band suggests that while the stock has experienced substantial highs, it has also faced considerable downward pressure, reflecting market uncertainty and sector-specific risks.

Today’s trading range between ₹448.00 and ₹470.50 indicates some intraday strength, but the overall price action remains cautious given the valuation concerns and recent performance trends.

Investor Takeaway: Balancing Growth Potential Against Valuation Risks

Investors analysing Shree Ganesh Remedies Ltd must weigh the company’s strong long-term returns and moderate profitability against its stretched valuation and recent underperformance. The elevated P/E and P/BV ratios suggest that much of the growth potential is already priced in, leaving limited margin of safety.

Comparisons with peers reveal that more attractively valued alternatives exist within the Pharmaceuticals & Biotechnology sector, some offering better risk-reward profiles. The recent downgrade to a Strong Sell rating by MarketsMOJO further emphasises the need for caution.

In summary, while Shree Ganesh Remedies Ltd remains a notable player with a history of robust returns, its current valuation shift to expensive territory and mixed recent performance signal that investors should carefully assess their exposure and consider diversification within the sector.

Upgrade at special rates, valid only for the next few days. Claim Your Special Rate →